|
|
||||||||

Division of Nuclear Medicine and Biophysics, Departments of Radiological Sciences, Pharmacology and Neurology and Laboratory of Nuclear Medicine, Laboratory of Biomedical and Environmental Sciences, UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California
Correspondence: For reprints contact: *John M. Hoffman, Section of Nuclear Medicine, Department of Radiology, Box 3808, Duke University Medical Center, Durham, NC 27710.
ABSTRACT
Carbidopa (L-
-hydrazino-
-methyl-b-(3,4-dihydroxyphenyl) propionic acid is a known inhibitor of aromatic amino acid decarboxylase. In both humans and monkeys, we studied the effects of carbidopa on plasma and brain kinetics of 6-[18F] fluoro-L-DOPA (FDOPA), an analog of L-DOPA used for PET studies of the central dopaminergic system. Pretreatment with carbidopa resulted in increases in the plasma levels of FDOPA and 3-O-methyl-6-[18F]fluoro-L-DOPA (3-OMFD). Total striatal and cerebellar activities measured with PET were also increased. Furthermore, increases observed in the specific striatal activity (striatum minus cerebellum total activity) were correlated with increases in the plasma FDOPA curve. Carbidopa pretreatment did not affect the influx rate constant (K) for FDOPA from plasma to striatum in humans as determined by Patlak graphical analysis. Thus, an increase in measured striatal tomographic activity was secondary to the increase in plasma FDOPA levels rather than as a result of changes in the FDOPA influx rate constant.
FOOTNOTES
* Current address: Section of Nuclear Medicine, Department of Radiology, Box 3808, Duke University Medical Center, Durham, NC 27710.
Current address: Cliniques Universitaire, De Bruxelles, Hospital Erasme, Route De Lennik 808, B-1070 Bruxelles, Belgium.
This article has been cited by other articles:
![]() |
S. Kauhanen, M. Seppanen, and P. Nuutila Premedication With Carbidopa Masks Positive Finding of Insulinoma and {beta}-Cell Hyperplasia in [18F]-Dihydroxy-Phenyl-Alanine Positron Emission Tomography J. Clin. Oncol., November 10, 2008; 26(32): 5307 - 5308. [Full Text] [PDF] |
||||
![]() |
P. L. Jager, R. Chirakal, C. J. Marriott, A. H. Brouwers, K. P. Koopmans, and K. Y. Gulenchyn 6-L-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications J. Nucl. Med., April 1, 2008; 49(4): 573 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J.L.M. Timmers, M. Hadi, J. A. Carrasquillo, C. C. Chen, L. Martiniova, M. Whatley, A. Ling, G. Eisenhofer, K. T. Adams, and K. Pacak The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma J. Nucl. Med., October 1, 2007; 48(10): 1599 - 1606. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Whone, D. L. Bailey, P. Remy, N. Pavese, and D. J. Brooks A Technique for Standardized Central Analysis of 6-18F-Fluoro-L-DOPA PET Data from a Multicenter Study J. Nucl. Med., July 1, 2004; 45(7): 1135 - 1145. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Ahlskog Slowing Parkinson's disease progression: Recent dopamine agonist trials Neurology, February 11, 2003; 60(3): 381 - 389. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |